Cabazitaxel

Cabazitaxel
Systematic (IUPAC) name
(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4-(Acetyloxy)-15-{[(2R,3S)-3-{[(tert-butoxy)carbonyl]amino}-2-hydroxy-3-phenylpropanoyl]oxy}-1-hydroxy-9,12-dimethoxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-ene-2-yl benzoate
Clinical data
Trade names Jevtana
AHFS/Drugs.com Consumer Drug Information
MedlinePlus a611009
Licence data EMA:Link, US FDA:link
  • US: D (Evidence of risk)
Intravenous
Identifiers
183133-96-2 
L01CD04
PubChem CID 9854073
DrugBank DB06772 Yes
ChemSpider 8029779 Yes
UNII 51F690397J Yes
ChEBI CHEBI:63584 
ChEMBL CHEMBL1201748 
Chemical data
Formula C45H57NO14
835.93 g/mol
  (what is this?)  (verify)

Cabazitaxel (previously XRP-6258, trade name Jevtana) is a semi-synthetic derivative of a natural taxoid.[1] It was developed by Sanofi-Aventis and was approved by the U.S. FDA for the treatment of hormone-refractory prostate cancer on June 17, 2010. It is a microtubule inhibitor, and the fourth taxane to be approved as a cancer therapy.[2]

Cabazitaxel in combination with prednisone is a treatment option for hormone-refractory prostate cancer following docetaxel-based treatment.

Clinical trials

In a phase III trial with 755 men for the treatment of castration-resistant prostate cancer, median survival was 15.1 months for patients receiving cabazitaxel versus 12.7 months for patients receiving mitoxantrone. Cabazitaxel was associated with more grade 3–4 neutropenia (81.7%) than mitoxantrone (58%).[3]

References

  1. ↑ http://www.cancer.gov/drugdictionary/?CdrID=534131
  2. ↑ "Jevtana (cabazitaxel) Injection Approved by U.S. FDA After Priority Review" (Press release). sanofi-aventis. 2010-06-17. Retrieved June 17, 2010.
  3. ↑ "Cabazitaxel Effective for Hormone Refractory Prostate Cancer After Failure of Taxotere".

External links